Senthil Raghavan, MD
Family Medicine · Little Rock, ARNPI 1912111055
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,215 of the $1,365 with a category attached, or 89.0%. It is spread thinly across 18 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $409, 7.9 times the $52 reported in 2019.
Across 54 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$287
- Amgen$199
- AbbVie$191
- Takeda Pharmaceuticals U.S.A., Inc.$150
- Idorsia Pharmaceuticals US Inc$112
- Novartis$101
- plus $325 from 12 others
Across 52 payments — averaging $9504.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$330K
- Novartis$145K
- Gilead$18K
- Caris MPI, Inc.$1K
- Boehringer Ingelheim RCV GmbH & Co KG$487
What the payments were for
- Speaking & faculty fees$15011%
- Food & beverage$1,21589%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $287 |
| Amgen | 5 | $199 |
| AbbVie(2 entities) | 11 | $191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $150 |
| Idorsia Pharmaceuticals US Inc | 1 | $112 |
| Novartis | 6 | $101 |
| Novo Nordisk | 1 | $94 |
| Exact Sciences | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| RGH Enterprises LLC | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,365 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $84,828 |
| TrulicityDulaglutide | 41 | $55,900 |
| JardianceEmpagliflozin | 41 | $45,459 |
| MounjaroTirzepatide | 33 | $45,318 |
| EliquisApixaban | 23 | $17,762 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,994 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,870 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $2,830 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,801 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,435 |
| Gabapentin | 153 | $2,422 |
| Atorvastatin Calcium | 274 | $1,793 |
| Diclofenac Sodium | 88 | $1,762 |
| Nifedipine ErNifedipine | 27 | $1,123 |
| Omeprazole | 69 | $1,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $94 | $84,82879 claims |
| Boehringer IngelheimJardiance | $11 | $45,45941 claims |
| PfizerEliquis | $12 | $17,76223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- Harold BettonLittle Rock$18K
- Kevin RobertsLittle Rock$15K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
- Oksana MelnykLittle Rock$12K
- Thomas MooreLittle Rock$11K
- Patrick FieldsLittle Rock$10K
- Gilbert FosterLittle Rock$10K
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.